Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Capital Expenditures (2016 - 2025)

Anaptysbio's Capital Expenditures history spans 10 years, with the latest figure at -$86000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 2.27% year-over-year to -$86000.0; the TTM value through Sep 2025 reached -$2000.0, down 100.53%, while the annual FY2024 figure was $7000.0, 99.13% down from the prior year.
  • Capital Expenditures reached -$86000.0 in Q4 2025 per ANAB's latest filing, down from $12000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $1.4 million in Q4 2021 to a low of -$228000.0 in Q2 2021.
  • Average Capital Expenditures over 5 years is $122842.1, with a median of $35000.0 recorded in 2024.
  • The largest YoY upside for Capital Expenditures was 6352.38% in 2021 against a maximum downside of 267.74% in 2021.
  • A 5-year view of Capital Expenditures shows it stood at $1.4 million in 2021, then tumbled by 102.14% to -$29000.0 in 2022, then skyrocketed by 1065.52% to $280000.0 in 2023, then tumbled by 131.43% to -$88000.0 in 2024, then increased by 2.27% to -$86000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANAB's Capital Expenditures are -$86000.0 (Q4 2025), $12000.0 (Q3 2025), and $39000.0 (Q2 2025).